RecruitingPhase 1NCT06367673

Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia

Clinical Study to Evaluate the Safety and Efficacy of iPSC -NK Cells Targeting CLL1 or CD33 in Patients With Relapsed/Refractory AML

Sponsor

Zhejiang University

Enrollment

24 participants

Start Date

Apr 30, 2024

Study Type

INTERVENTIONAL

Conditions

AML, Adult

Summary

This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of immune cell therapy using natural killer (NK) cells engineered to target cancer cells in people with relapsed or refractory acute myeloid leukemia (AML), a blood cancer that has returned or stopped responding to prior treatment. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of relapsed or refractory AML - Your cancer cells test positive for CLL1 or CD33 proteins - You have a good performance status (ECOG 0 or 1) and life expectancy of more than 12 weeks - Your organ function meets the required thresholds **You may NOT be eligible if...** - You have active, uncontrolled infection - You have significant organ damage beyond study thresholds - You are pregnant or breastfeeding - You have received prior NK cell therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.